A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV-Reference-Cited by-同舟云学术

A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

Published:2022-08-17 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Cheng Shu-Hsing¹,Lien Chia En²,Hsieh Szu-Min³,Cheng Chien-Yu¹,Liu Wang-Da³,Lo Ching-Lung⁴,Ko Wen-Chien⁴,Chen Yen-Hsu⁵,Huang Ching-Tai⁶,Chang Hsiao-Ting⁷,Hwang Shinn-Jang⁷,Wang Ning-Chi⁸,Liu Ming-Che⁹,Lee Yu-Lin¹⁰,Tai I-Chen²,Estrada Josue Antonio Garcia²,Lin Tzou-Yien¹¹,Lee Wen-Sen⁹

Affiliation:

1. Taoyuan General Hospital, Ministry of Health and Welfare

2. Medigen Vaccine Biologics

3. National Taiwan University Hospital

4. National Cheng Kung University Hospital

5. Kaohsiung Medical University Hospital

6. Chang Gung Memorial Hospital

7. Taipei Veterans General Hospital

8. Tri-Service General Hospital

9. Taipei Medical University

10. Changhua Christian Hospital

11. Chang Gung University

Abstract

Abstract Safety and immunogenicity of MVC-COV1901, a recombinant COVID-19 protein vaccine, containing S-2P protein adjuvanted with CpG 1018 and aluminium hydroxide, was assessed for people living with HIV (PWH). A total of 57 PWH of ≥ 20 years of age who are on stable antiretroviral therapy were compared with 882 HIV-negative participants. Participants received 2 doses of MVC-COV1901 28 days apart. No vaccine-related serious adverse events (SAEs) were recorded. Seroconversion rates (SCRs) of 100% and 99.8% were achieved in PWH and comparators, respectively, 28 days after second dose. After adjusting for sex, age, BMI category, and comorbidity, the adjusted GMT ratio of comparator/PWH was 3.2 (95% CI 2.5-4). A higher CD4/CD8 ratio was associated with a higher GMT (R = 0.27, p = 0.039). MVC-COV1901 has shown robust safety but elicited weaker immune responses in PWH. As a result, a third dose or booster doses of MVC-COV1901 may be appropriate for PWH.ClinicalTrials.gov registration: NCT04695652.

Publisher

Research Square Platform LLC

Reference55 articles.

1. World Health Organization. WHO Director-General's opening remarks at the mission briefing on COVID-19-11 March 2020. World Health Organization. March 11, 2020. Available at. WHO 2020 March 11Available from: URL: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed June 5, 2021.

2. A pneumonia outbreak associated with a new coronavirus of probable bat origin;Zhou P;Nature,2020

3. Done E, Du I, Garder L. COVID-19 Dashboard by the Centrefor Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). John Hopkins University 2020 March 31. Available from: URL: Available at https://coronavirus.jhu.edu/map.html. Accessed Mar/31/ 2022.

4. Yancy CW. COVID-19 and African Americans. JAMA 2020 May 19;323(19):1891-2.

5. Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med 2015 Mar 3;162(5):335 – 44.